vimarsana.com
Home
Live Updates
Non-Lab Diagnostics: FDA Regulatory Considerations | MoFo Li
Non-Lab Diagnostics: FDA Regulatory Considerations | MoFo Li
Non-Lab Diagnostics: FDA Regulatory Considerations | MoFo Life Sciences
The advent of the COVID-19 rapid antigen test launched at-home diagnostics to the forefront of conversation in the life sciences industry. Many believe this is only the beginning. As...
Related Keywords
William Rinehart ,
Utah State University ,
Mofo Life Sciences ,
Laboratory Developed ,
Public Health Service ,
Mofo Life ,
Federal Food ,
Cosmetics Act ,
Are Not ,
System Regulation ,
Device Reporting ,
Proposed Rule ,
Medical Devices ,
Laboratory Developed Tests ,
Draft Guidance ,
Clinical Laboratories ,
Regulatory Oversight ,
Consumer Tests ,
Drug Admin ,
Evaluating Substantial Equivalence ,
Premarket Notifications ,
Device Manufacturers ,
Vitro Diagnostic Device Labeling Requirements ,
Antigen Home Use Test Template ,
Vitro Diagnostics ,
Antigen Diagnostic Tests ,
Lessons Learned ,